Evogene Stock News

Evogene (NASDAQ:EVGN) had its price objective trimmed by Royal Bank of Canada from $8.00 to $7.00 in a research report report published on Wednesday morning, Stock Target Advisor reports. The firm currently has an outperform rating on the biotechnology companys stock. EVGN has been the subject of a number of other research reports. Roth Capital []

LPL Financial LLC lifted its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 21.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,485 shares of the biotechnology companys stock after purchasing an additional 10,625 shares during the quarter. LPL Financial LLC []

Evogene (NASDAQ:EVGN) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by ($0.02), MarketWatch Earnings reports. Evogene had a negative net margin of 2,326.70% and a negative return on equity of 38.88%. During the same quarter in the prior year, []

Evogene (EVGN) CEO, Ofer Haviv on Q3 2021 Results - Earnings Call Transcript

Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), the parent company of medical cannabis-focused Canonic, reported its financial results Wednesday for the first nine months and third quarter of 2021.

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to sha

Evogene Ltd.'s (NASDAQ:EVGN) (TASE: EVGN) wholly-owned subsidiary focused on developing medical cannabis products, Canonic Ltd.

REHOVOT, Israel, Sept. 14, 2021 /PRNewswire/ -- Evogene Ltd.

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Evogene (EVGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Evogene Ltd. (EVGN) CEO Ofer Haviv on Q2 2021 Results - Earnings Call Transcript

Biotechnology company Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) posted its financial results Wednesday for the first half and second quarter of 2021 along with a proclamation from the company's presid